|
1
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO Classification of Tumours of the Digestive System
(4th). Lyon: IARC Press. 2010.
|
|
2
|
Carcas LP: Gastric cancer review. J
Carcinog. 13:142014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marrelli D, Polom K, de Manzoni G,
Morgagni P, Baiocchi GL and Roviello F: Multimodal treatment of
gastric cancer in the west, Where are we going? World J
Gastroenterol. 21:7954–7969. 2015.PubMed/NCBI
|
|
4
|
Kasper DL, Fauci A, Hauser S, Longo D,
Jameson J and Loscalzo J: Harrison's Principles of Internal
Medicine (19th). New York, NY: McGraw-Hill Education. 2015.
|
|
5
|
Koizumi W: Chemotherapy for advanced
gastric cancer: R eview of global and Japanese status. Gastrointest
Cancer Res. 1:197–203. 2007.PubMed/NCBI
|
|
6
|
Aggarwal S: Targeted cancer therapies. Nat
Rev Drug Discov. 9:427–428. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelman JA and Settleman J: Acquired
resistance to tyrosine kinase inhibitors during cancer therapy.
Curr Opin Genet Dev. 18:73–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gherardi E, Birchmeier W, Birchmeier C and
Vande Woude G: Targeting MET in cancer. Rationale and progress. Nat
Rev Cancer. 12:89–103. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hara T, Ooi A, Kobayashi M, Mai M,
Yanagihara K and Nakanishi I: Amplification of c-myc, K-sam and
c-met in gastric cancers, Detection by fluorescence in situ
hybridization. Lab Invest. 78:1143–1153. 1998.PubMed/NCBI
|
|
11
|
Scagliotti GV, Novello S and von Pawel J:
The emerging role of MET/HGF inhibitors in oncology. Cancer Treat
Rev. 39:793–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Guessous F, Kofman A, Schiff D
and Abounader R: XL-184, a MET, VEGFR-2 and RET kinase inhibitor
for the treatment of thyroid cancer, glioblastoma multiforme and
NSCLC. IDrugs. 13:112–121. 2010.PubMed/NCBI
|
|
13
|
Hoy SM: Cabozantinib: A review of its use
in patients with medullary thyroid cancer. Drugs. 74:1435–1444.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY,
Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, et al: Evaluation of a
multi-kinase inhibitor KRC-108 as an anti-tumor agent in
vitro and in vivo. Invest New Drugs. 30:518–523. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McDermott U, Sharma SV, Dowell L,
Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A,
Lee D, et al: Identification of genotype-correlated sensitivity to
selective kinase inhibitors by using high-throughput tumor cell
line profiling. Proc Natl Acad Sci USA. 104:19936–19941. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gumbiner BM: Cell adhesion: T he molecular
basis of tissue architecture and morphogenesis. Cell. 84:345–357.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takeichi M: Cadherin cell adhesion
receptors as a morphogenetic regulator. Science. 251:1451–1455.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiscox S and Jiang WG: Association of the
HGF/SF receptor c-met, with the cell-surface adhesion molecule,
E-cadherin and catenins in human tumor cells. Biochem Biophys Res
Commun. 261:406–411. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reshetnikova G, Troyanovsky S and Rimm DL:
Definition of a direct extracellular interaction between Met and
E-cadherin. Cell Biol Int. 31:366–373. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Götte M, Kersting C, Radke I, Kiesel L and
Wülfing P: An expression signature of syndecan-1 (CD138),
E-cadherin and c-met is associated with factors of angiogenesis and
lymphangiogenesis in ductal breast carcinoma in situ. Breast
Cancer Res. 9:R82007. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
McDermott U, Pusapati RV, Christensen JG,
Gray NS and Settleman J: Acquired resistance of non-small cell lung
cancer cells to MET kinase inhibition is mediated by a switch to
epidermal growth factor receptor dependency. Cancer Res.
70:1625–1634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi J, McTigue MA, Rogers A, Lifshits E,
Christensen JG, Jänne PA and Engelman JA: Multiple mutations and
bypass mechanisms can contribute to development of acquired
resistance to MET inhibitors. Cancer Res. 71:1081–1091. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tiedt R, Degenkolbe E, Furet P, Appleton
BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD,
et al: A drug resistance screen using a selective met inhibitor
reveals a spectrum of mutations that partially overlap with
activating mutations found in cancer patients. Cancer Res.
71:5255–5264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gorre ME, Mohammed M, Ellwood K, Hsu N,
Paquette R, Rao PN and Sawyers CL: Clinical resistance to STI-571
cancer therapy caused by BCR-ABL gene mutation or amplification.
Science. 293:876–880. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thompson EW and Haviv I: The social
aspects of EMT-MET plasticity. Nat Med. 17:1048–1049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie M, Zhang L, He CS, Xu F, Liu JL, Hu
ZH, Zhao LP and Tian Y: Activation of Notch-1 enhances
epithelial-mesenchymal transition in gefitinib-acquired resistant
lung cancer cells. J Cell Biochem. 113:1501–1513. 2012.PubMed/NCBI
|
|
29
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of
non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res.
65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mahadevan D, Cooke L, Riley C, Swart R,
Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H,
et al: A novel tyrosine kinase switch is a mechanism of imatinib
resistance in gastrointestinal stromal tumors. Oncogene.
26:3909–3919. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oliveira MJ, Costa AM, Costa AC, Ferreira
RM, Sampaio P, Machado JC, Seruca R, Mareel M and Figueiredo C:
CagA associates with c-met, E-cadherin and p120-catenin in a
multiproteic complex that suppresses Helicobacter
pylori-induced cell-invasive phenotype. J Infect Dis.
200:745–755. 2009. View
Article : Google Scholar : PubMed/NCBI
|
